USPTO Grants Patent for Sulfur Compound in Tumor Treatment
Summary
The USPTO has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY for a sulfur-containing compound based on a glutarimide skeleton and its application in treating tumors. The patent filing date was February 25, 2020, and the grant date is March 24, 2026.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY. This patent covers a sulfur-containing compound based on a glutarimide skeleton and its application for treating tumors. The patent abstract details compounds of Formula (I) or (I') and their use, including salts, solvates, and stereoisomers.
This patent grant represents a new intellectual property asset for SHANGHAITECH UNIVERSITY in the field of oncology therapeutics. While this is a patent grant and not a regulatory rule, it signifies a new development in drug discovery that may impact future pharmaceutical development and commercialization strategies. Compliance officers in the pharmaceutical sector should be aware of this patent as it pertains to potential new treatments and associated intellectual property rights.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Sulfur-containing compound based on glutarimide skeleton and application thereof
Grant US12582641B2 Kind: B2 Mar 24, 2026
Assignee
SHANGHAITECH UNIVERSITY
Inventors
Xiaobao Yang, Biao Jiang, Xing Qiu, Ning Sun, Renhong Sun, Linyi Liu, Chaowei Ren
Abstract
The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.
CPC Classifications
A61K 31/4545 A61K 31/454 A61K 31/4709 A61K 31/496 A61K 31/506 A61K 31/517 A61K 31/5377 A61K 31/541 A61K 31/55 A61K 31/551 A61K 45/06 A61P 35/00 A61P 7/06 A61P 35/02 C07D 401/04 C07D 401/14 C07D 405/14 C07D 409/14 C07D 413/14 C07D 471/04 C07D 471/08 C07D 491/107 C07D 417/14 C07D 453/02 C07D 487/08 C07F 9/65583 C07F 9/6558
Filing Date
2020-02-25
Application No.
17433462
Claims
53
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.